AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer

AstraZeneca received FDA accelerated approval for Etcamah (camizestrant), used with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative advanced breast cancer. The approval expands AstraZeneca's oncology portfolio and provides an earlier commercial pathway for the treatment, though continued clinical confirmation is generally required under the accelerated-approval framework.